Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis
CONCLUSIONS: These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.PMID:37964648 | DOI:10.5603/cj.90956 (Source: Cardiology Journal)
Source: Cardiology Journal - November 15, 2023 Category: Cardiology Authors: Junyan Zhang Zhongxiu Chen Duolao Wang Chen Li Fangbo Luo Yong He Source Type: research
Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis
CONCLUSIONS: These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.PMID:37964648 | DOI:10.5603/cj.90956 (Source: Cardiology Journal)
Source: Cardiology Journal - November 15, 2023 Category: Cardiology Authors: Junyan Zhang Zhongxiu Chen Duolao Wang Chen Li Fangbo Luo Yong He Source Type: research
Bivalirudin in acute coronary syndromes
Expert Rev Cardiovasc Ther. 2023 Nov 2. doi: 10.1080/14779072.2023.2273902. Online ahead of print.ABSTRACTINTRODUCTION: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).AREAS COVERED: Despite showing a superior safety profile compared with unfractionated heparin (UFH), bivalirudin is not considered the anticoagulant of choice in ACS patients undergoing PCI, mainly because of an increased rate of acute stent thrombosis (ST) showed by several randomiz...
Source: Expert Review of Cardiovascular Therapy - November 3, 2023 Category: Cardiology Authors: Mattia Galli Marco Bernardi Luis Ortega-Paz Roberto Nerla Domenico D'Amario Francesco Franchi Giuseppe Biondi-Zoccai Dominick J Angiolillo Source Type: research
Evaluation of Newly Integrated Bivalirudin Titration Protocol in Patients With Mechanical Circulatory Support
CONCLUSIONS: Implementation of the bivalirudin titration nomograms within the EHR significantly increased the number of therapeutic aPTTs, reduced the number of patients who never achieved a therapeutic aPTT, and reduced the required number of titrations per day.PMID:37887435 | DOI:10.1177/10600280231206130 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 27, 2023 Category: Drugs & Pharmacology Authors: Madeline Mitchell Danine Sullinger Duke Dyer Gavin Hickey David Kaczorowski Joni Minor Holt Murray Raj Ramanan Zachary Rhinehart Mark Schmidhofer Ryan M Rivosecchi Source Type: research
Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
Exp Ther Med. 2023 Sep 27;26(5):530. doi: 10.3892/etm.2023.12229. eCollection 2023 Nov.ABSTRACTBivalirudin, as a direct thrombin inhibitor, is considered to be safer compared with other anticoagulants, such as heparin; however, relevant data in China are unclear. The present study aimed to compare the safety of bivalirudin and heparin as anticoagulants in Chinese patients who underwent percutaneous coronary intervention (PCI). In the present study, 2,377 patients with ST-segment elevation myocardial infarction (STEMI), unstable angina, non-STEMI or stable coronary artery disease who underwent primary PCI while receiving bi...
Source: Experimental and Therapeutic Medicine - October 23, 2023 Category: General Medicine Authors: Lina Chai Jinjun Liu Yapei Zhang Mengying Zhang Zhenzhen Wang Yiping Wu Zhichao Bai Zhenpeng Qin Source Type: research
